ROCKVILLE, Md., USA and SUZHOU, China, Feb. 13, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that it has received clearance from…
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA
This post was originally published on this site